Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18682190 | 0.89 | TSHR (0.33) | HPGDALDH1A1HSD17B10MDM2LMNA | |
| SCHEMBL17069268 | 0.80 | POLB (0.40) | HPGDMDM2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL15113319 | 0.69 | TRPA1 (0.46) | ALDH1A1MDM2KDM4EAPP | |
| SCHEMBL31413689 | 0.68 | APP (0.39) | HPGDALDH1A1HSD17B10LMNAMAPT | |
| SCHEMBL13707877 | 0.67 | POLB (0.51) | HPGDLMNAMAPTSMN1; SMN2TSHR | |
| SCHEMBL19426091 | 0.67 | SCN9A (0.32) | — | |
| SCHEMBL10137798 | 0.65 | TP53 (0.39) | HPGDALDH1A1HSD17B10LMNAMAPT | |
| SCHEMBL12438055 | 0.65 | TRPA1 (0.47) | ALDH1A1MDM2LMNASMN1; SMN2TSHR | |
| SCHEMBL19388171 | 0.64 | ALDH1A1 (0.48) | ALDH1A1MDM2LMNAKDM4E | |
| SCHEMBL421965 | 0.63 | AKR1C4 (0.60) | HPGDALDH1A1HSD17B10LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | HPGD 3276/4885ALDH1A1 1503/4885HSD17B10 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.